AXL-Driven EMT State as a Targetable Conduit in Cancer

scientific article published on 30 June 2017

AXL-Driven EMT State as a Targetable Conduit in Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/0008-5472.CAN-17-0392
P698PubMed publication ID28667075

P50authorJane AntonyQ57149743
P2093author name stringRuby Yun-Ju Huang
P2860cites workThe Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer TherapyQ27928010
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerQ36128435
P433issue14
P407language of work or nameEnglishQ1860
P304page(s)3725-3732
P577publication date2017-06-30
P13046publication type of scholarly workreview articleQ7318358
P1433published inCancer ResearchQ326097
P1476titleAXL-Driven EMT State as a Targetable Conduit in Cancer
P478volume77

Reverse relations

cites work (P2860)
Q92814606AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
Q64073169AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Q92323801Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors
Q92043014Contribution of Epithelial Plasticity to Therapy Resistance
Q60950078Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics
Q100490624Emerging role of tumor cell plasticity in modifying therapeutic response
Q96762441Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers
Q94465946Gas6 expression is reduced in advanced breast cancers
Q90218507Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers
Q90364525HOXB4 promotes the malignant progression of ovarian cancer via DHDDS
Q92882432Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics
Q91698979METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition
Q100516162Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment
Q52714580Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance.
Q91886062Molecular dissection of the oncogenic role of ETS1 in the mesenchymal subtypes of head and neck squamous cell carcinoma
Q89574633Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade
Q99579024Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma
Q52589214RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade
Q92838091Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Q96128242Skipping of exon 10 in Axl pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells
Q93193163Soluble AXL is ubiquitously present in malignant serous effusions
Q89393296Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?
Q64253749Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys"
Q64951234Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation.
Q97542845The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma
Q89121009The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
Q94458496Tumor Plasticity and Resistance to Immunotherapy

Search more.